Page 5 - Sun Pharma

Indian drugmakers face risks as Trump eyes tariffs on US imports of pharma

The company relies on its key generic drugs in oncology and immunology therapies for sales in the region, which rose 28 per cent from a year earlier

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Ajit Mishra of Religare Broking suggests buying these two stocks today

Bharti Airtel has emerged from a consolidation phase, indicating a continuation of its uptrend

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Dividend, Stock-split: Sun Pharma, Ksolves, 5 others to go ex-date tomorrow

Here are the complete details of companies whose shares will trade ex-date tomorrow, along with their corporate announcements and key details

Brokerages offer mixed views on Sun Pharma post steady Q3; buy, sell, hold?

While Sun Pharma continues to demonstrate strength in its branded and specialty businesses, concerns around US generics, R&D investments, and regulatory hurdles leave brokerages divided on its outlook

Sun Pharma Q3FY25 results: Net profit soars 15%, revenue up 10.5%

Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent. Both profit and revenue were in line with Bloomberg estimates

Sun Pharma Q3FY25 results: Net profit soars 15% to Rs 2,903.3 crore

Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent

Sun Pharma Q3 results: Net profit up 15% at Rs 2,905 cr on strong sales

Sales in India, Sun Pharma's largest revenue-generating region, rose 14 per cent to Rs 4,300 crore, or about 31 per cent of total sales

Q3 results, Jan 31: Pfizer, Sun Pharma, ONGC, Nestle to post earnings today

Q3 FY25 company results, January 31: Vedanta, Nuvama, Punjab National Bank, IndusInd Bank, and Bandhan Bank will be among 135 companies to release their reports for the Oct-Dec quarter

Sun Pharma Q3 Preview: Profits may jump 13%, revenues to rise 10% YoY

According to brokerage estimates compiled by Business Standard, Sun Pharma may see its average revenue rise by 9.51 per cent year-on-year (Y-o-Y) to Rs 13,313 crore as against Rs 12,156 crore

Sun Pharma's unit Taro to acquire 100% stake in Antibe Therapeutics

The acquisition is expected to be completed before March 7, 2025, subject to approval from the Ontario Superior Court of Justice

Sun Pharma sells entire stake in Japanese arm to Zaza Industrial Holdings

According to a regulatory filing with BSE, the agreement was signed on December 31, 2024, with the transaction expected to be completed by January 31, 2025

Stocks to Watch, January 1, 2025: Auto stocks, ITC, Sun Pharma, Piramal Ent

The previous session closed out 2024 with mixed sentiments. Despite a strong recovery from intraday lows, the benchmarks ended in the red, weighed down by losses in IT & select banking shares

Nandish Shah of HDFC Sec suggests 'Bull Spread' strategy on Sun Pharma

Long rollover is seen in the Sun Pharma Futures to the January series, where we have seen 34 per cent rise in the open interest with price rising by 1.23 per cent

Despite short-term blip, Sun Pharma remains favourite among investors

According to Bloomberg, 30 of 41 analysts are bullish on Sun Pharma, while the remaining seven have a neutral rating and only 4 are bearish

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Stocks to Watch, Nov 29: SBI, PC Jeweller, Nazara Tech, Adani Group shares

Stocks to Watch, Nov 29: Here are few stocks that will remain in focus for today's session

Sun Pharma's Leqselvi launch in US faces legal roadblock; analysts cautious

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company wins its appeal, or up to two years if it loses the case entirely

Sun Pharma slips 5% as US court bars it from launching alopecia drug

Given the investments of around $576 million and the peak revenues potential upwards of $200 million, four years down the line, ICICI Securities expects some negative impact on the company